COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥700 | ¥503 | ¥525 | ¥483 |
| - Cash | ¥57 | ¥52 | ¥46 | ¥37 |
| + Debt | ¥50 | ¥34 | ¥18 | ¥9 |
| Enterprise Value | ¥693 | ¥485 | ¥497 | ¥455 |
| Revenue | ¥1,011 | ¥965 | ¥828 | ¥755 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Gross Profit | ¥213 | ¥188 | ¥169 | ¥151 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| EBITDA | ¥65 | ¥54 | ¥50 | ¥48 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |
| Net Income | ¥31 | ¥24 | ¥24 | ¥23 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS Diluted | 390.85 | 308.61 | 300.48 | 292.37 |
| % Growth | 26.6% | 2.7% | 2.8% | – |
| Operating Cash Flow | ¥52 | ¥52 | ¥55 | ¥54 |
| Capital Expenditures | -¥53 | -¥53 | -¥56 | -¥47 |
| Free Cash Flow | -¥1 | -¥1 | -¥1 | ¥8 |